Population pharmacokinetics of omeprazole in obese and normal-weight adults

CONCLUSION: Given the potential adverse events related to high exposure to proton pump inhibitors over time, obese patients may require a lower dose of omeprazole for long-term treatment. Further studies in obese individuals into other drugs metabolized by CYP2C19 are warranted, especially those with a narrow therapeutic window.CLINICAL TRIAL REGISTRATION: www.chictr.org.cn identifier is ChiCTR2100046578; www.chinadrugtrials.org.cn identifier is CTR20190175.PMID:35522794 | DOI:10.1080/17512433.2022.2075343

Source: Pharmacological Reviews - May 6, 2022 Category: Drugs & Pharmacology Authors: Kaifeng Chen Ping Luo Guoping Yang Shaihong Zhu Chenhui Deng Junjie Ding Yaqi Lin Liyong Zhu Qi Pei Source Type: research